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•  There are sparse data on continued efficacy of anticoagulants in extended 
prophylactic period. 
•  We assumed, in the base case, that aspirin did not increase the risk of 
bleeding. We addressed the uncertainty in this parameter in sensitivity 
analyses. 
•  Prolonged therapies increase QALYs compared to standard duration 
therapies, supporting the extension of anticoagulation post-TKA. 
•  Prolonged prophylaxis with warfarin and rivaroxaban emerged as cost-
effective strategies. 
•  As prolonged rivaroxaban and warfarin are comparable from a cost-
effectiveness standpoint, patient preferences can help inform the choice of 
the appropriate postoperative anticoagulation strategy. 
Increase in costs (dollars) 
Increase in health benefits (QALYs) 
•  Anticoagulation is essential for deep vein thrombosis (DVT) and 
pulmonary embolism (PE) prevention following total knee 
arthroplasty (TKA) 
•  Prolonging the duration of anticoagulation post-TKA can 
substantially reduce DVT and PE risks 
•  Clinicians must weigh the risks of DVT and PE against those of 
excessive anticoagulation, including hemorrhage and prosthetic 
joint infection (PJI) 
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Figure 1. Model Structure 
Table 2. Cost-effectiveness of anticoagulation strategies after TKA 
Regimen Cost QALY ICER DVT Bleed 
Prolonged Rivaroxaban	 $3,279	 0.7328	 Cost Saving	 18.0%	 6.0%	
Prolonged Warfarin	 $3,291	 0.7325	 Cost Saving	 21.9%	 4.0%	
Standard Rivaroxaban	 $3,416	 0.7322	 Cost Saving	 22.8%	 5.4%	
Standard Warfarin	 $3,551	 0.7319	 Reference	 25.6%	 3.9%	
Prolonged Asprin	 $3,689	 0.7315	 Dominated	 25.7%	 3.5%	
Standard Aspirin	 $3,777	 0.7312	 Dominated	 28.4%	 3.4%	
No prophylaxis	 $3,869	 0.7262	 Dominated	 32.1%	 3.3%	
Standard LMWH	 $3,898	 0.7321	 Dominated	 23.9%	 3.9%	
Standard Fondaparinux	 $3,932	 0.7323	 $977,100	 22.3%	 5.6%	
Prolonged LMWH	 $4,375	 0.7326	 Dominated	 19.5%	 4.1%	
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•  Evaluate the cost-effectiveness of prolonged (35-day) and 
standard (14-day) duration anticoagulation therapy following TKA 
Results 
Table 1. Select Input Parameters 
Anticoagulation Characteristics 
Daily Cost RR DVT RR Bleeding 
Fondaparinux $431 0.08 2.21 
Rivaroxaban $8 0.12 2.12 
LMWH $371 0.20 1.23 
Warfarin $6/$32 0.36 1.21 
Aspirin $1 0.69 1.0 
LMWH – low molecular weight heparin 
1 – Includes cost of injection administration ($20) 




Model Structure (Figure 1) 
•  State-transition Monte-Carlo computer simulation model (TreeAge 
Pro©) following subjects for one year post-TKA, tracking clinical 
and economic outcomes of TKA and anticoagulation therapy 
•  Subjects transition between the following major health states 
post-TKA: 
•  DVT, PE, PJI, hemorrhage, no postoperative complications 
 
Input Data (Table 1) 
•  Published literature, RedBook Online®, Medicare Fee Schedules 
•  Each anticoagulant associated with unique cost, efficacy, and 
bleeding risk 




•  Anticoagulants considered: 
•  Fondaparinux, Rivaroxaban, Low molecular weight heparin 
(LMWH), Warfarin, Aspirin 
•  Duration of post-TKA anticoagulation: 
•  Standard duration (14-day) or Prolonged duration (35-day) 
 
Outcomes: 
•  Proportion of first post-operative year spent in each health state 
•   Incremental cost-effectiveness ratio (ICER): 






















PJI + Post-PJI 
Bleed + Post-Bleed 
PE + Post-PE 
DVT + Post-DVT 
No complications 
75% 80% 78% 80% 80% 
12% 15% 18% 13% 12% 
5% 3% 3% 3% 5% 
Figure 4. Proportion of the First Postoperative Year Spent in Each Health 
State for Prolonged Strategies 
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